AusBiotech advocates at Federal Department of Health forums on regulation

11 August 2015
2019_biotech_test_vial_discovery_big

AusBiotech, the representative body for the Australian biotech industry, advocated at an invitation-only forum held by the Deregulation Branch of the Federal Department of Health.

The forum was held to discuss the first report on the review of medicines and medical devices regulation, released on March 31 2015.

The forums, on medicines, medical devices, and unapproved products, were held so that stakeholders could give feedback and discuss the practical implications of proposed approaches.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology